Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Enzon 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Enzon 2Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Enzon

2Q Revenues: $51.0 million (+4%)

2Q Loss: $1.7 million (loss of $2.0 million in 2Q07)

Comments: Contract manufacturing revenue was $6.7 million in the quarter, up 14% due to deliverables. The company warned that it likely will not maintain contract revenues at that level during the rest of the year. Product sales were $29.2 million (+17%), driven by Oncaspar sales up 36% to 13.2 million, DepoCyt sales up 14% to $2.4 million, and Adagen sales up 7% to $7.0 million. Royalties were $15.0 million in the quarter (-18%), impacted by the sale of its royalty interest in Peg-Intron in August 2007.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters